Akero Therapeutics Inc

Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced the appointment of Scott Gangloff as Chief Technology Officer.

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 25, 2024. SO WHAT: If you purchased Akero common stock during the.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Akero business and prospects, resulting in its stock trading at inflated prices.

AKRO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 25, 2024 to file lead plaintiff applications in a securities class action lawsuit against Akero Therapeutics, Inc. (NasdaqGS: AKRO), if they purchased or otherwise acquired the Company's shares between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”). This action is pending in the United Sta.

AKERO THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO

NEW YORK , April 28, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ: AKRO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO

MILWAUKEE , April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Akero (Nasdaq: AKRO). The investigation results from inaccurate statements Akero may have made regarding its business operations and prospects.

Ademi LLP Investigates Claims of Securities Fraud against Akero Therapeutics, Inc.

NEW YORK, NY / ACCESSWIRE / April 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Akero Therapeutics, Inc. ("Akero Therapeutics") (NASDAQ:AKRO) concerning possible violations of federal securities laws. On October 10, 2023, AKRO announced Efruxifermin (EFX) failed to meet the primary endpoint of fibrosis improvement at 36 weeks in the Phase 2B SYMMETRY trial in NASH patients with compensated cirrhosis.

Levi & Korsinsky Reminds Shareholders of an Investigation into Akero Therapeutics, Inc. (AKRO) Regarding Potential Securities Fraud Allegations

NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Akero Therapeutics, Inc. ("Akero Therapeutics") (NASDAQ:AKRO) concerning possible violations of federal securities laws. On October 10, 2023, AKRO announced Efruxifermin (EFX) failed to meet the primary endpoint of fibrosis improvement at 36 weeks in the Phase 2B SYMMETRY trial in NASH patients with compensated cirrhosis.

Akero Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – AKRO

NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Akero Therapeutics, Inc. ("Akero Therapeutics") (NASDAQ:AKRO) concerning possible violations of federal securities laws. On October 10, 2023, AKRO announced Efruxifermin (EFX) failed to meet the primary endpoint of fibrosis improvement at 36 weeks in the Phase 2B SYMMETRY trial in NASH patients with compensated cirrhosis.

Akero Therapeutics, Inc. (AKRO) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

Shareholder Rights Advocates at Levi & Korsinsky Investigate Akero Therapeutics, Inc. (AKRO) Regarding Possible Securities Fraud Violations

SOUTH SAN FRANCISCO, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,650,000 shares of common stock in this offering. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $366.9 million.

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable to that of EFX alone and led to statistically significant improvements in non-invasive markers of liver injury and fibrosis and of metabolic health

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $29.00 per share. All of the shares in the offering are being offered by Akero Therapeutics. In addition, Akero Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $319.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about March 8, 2024, subject to the satisfaction of customary closing conditions.

Akero Therapeutics Announces Pricing of Public Offering of Common Stock

Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today that it has commenced an underwritten public offering of $300.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Akero Therapeutics. In addition, Akero Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Akero Therapeutics Announces Proposed Public Offering of Common Stock

Akero Therapeutics, Inc. preliminary positive 96-week results from the phase 2b HARMONY study achieved, which used EFX for the treatment of pre-cirrhotic MASH patients with F2-F3 Fibrosis. The global non-alcoholic steatohepatitis market size is expected to reach $14.53 billion by 2028. 96-week results from the phase 2b SYMMETRY study, using EFX for the treatment of patients with compensated cirrhosis (F4) MASH, expected in Q1 of 2024.

Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program

89bio Inc

Biotech stocks Akero Therapeutics and 89bio rocketed Monday after the former announced promising test results for a liver disease treatment.

Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment

Akero Therapeutics said on Monday its lead experimental drug to treat a type of fatty liver disease helped improve scarring in patients' organ after 96 weeks, meeting the main goal of a mid-stage study.

Akero's lead drug helps improve scarring in fatty liver disease patients

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

The mean of analysts' price targets for Akero Therapeutics, Inc. (AKRO) points to a 58.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know

Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data

Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH

SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2023.

Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Akero Therapeutics, Inc. (AKRO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Akero Therapeutics, Inc. (AKRO) Is a Great 'Buy the Bottom' Stock Now

Here is how Akero Therapeutics, Inc. (AKRO) and Perspective Therapeutics (CATX) have performed compared to their sector so far this year.

Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?

The shares of Akero Therapeutics Inc (NASDAQ:AKRO) have been steadily climbing from their November lows following a steep early October bear gap , though pressure seems to have appeared at the $25 level.

News for Akero Therapeutics Inc Stock (AKRO)